14 Jan

The ultimate success of the Bristol-Myers’ Celgene purchase could hinge on one upcoming trial

Biggest life sciences M&A deal for nearly two decades may turn out to be a damp squib if Dr Reddy’s wins a suit relating to follow-on patents that cover flagship cancer treatment Revlimid

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth